Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive tracer lets scientists follow a drug through the human body

NCT ID NCT07839000

Knowledge-focused Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 24, 2026 · Last updated Sep 25, 2026 · Updated 1 time

Summary

Researchers want to learn what happens to the oral drug TERN-701 inside the body. They give a single dose tagged with a tiny radioactive tracer to eight healthy adult men, then collect blood, urine, and stool samples over time. The samples show how much of the drug is absorbed, how it is broken down, and how it leaves the body. This kind of early study helps scientists understand a drug's journey before testing it in patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TERN-701, an oral drug tagged with a tiny radioactive tracer so researchers can follow it through the body
What this could lead to
If it works, this could give researchers a clear picture of how the body processes TERN-701, which may help guide later studies of the drug.
What could go wrong
This is a very early, tiny study in eight healthy men, so its findings may not apply to women, sick patients, or people with different body types. The radioactive tracer carries a small dose of radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

8 people

The number who actually took part.

Started

Feb 2026

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has body mass index (BMI) ≥18.5 and ≤32.0 kg/m\^2 * Is in good health Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has history or presence of any medical condition or prior surgery that may impact typical absorption, distribution, metabolism, or excretion of the orally administered study drug (e.g., gastric bypass, gastrointestinal dysmotility, irritable or inflammatory bowel disease) * Has history or laboratory evidence of hyperthyroidism (thyroid-stimulating hormone \[TSH\] \< lower limit of normal \[LLN\]) or hypothyroidism (TSH ≥8 mIU/L) * Has history of cancer that has not been in complete remission for \> 5 years (except basal cell skin cancer or squamous cell skin cancer with a history of curative treatment and no recurrence for \> 1 year prior) * Has history of dysphagia, aspiration, or other conditions that could potentially impede the ability to safely orally ingest the study drug per protocol * Has history of incomplete bladder emptying with voiding (i.e., urinary retention) or recent history of awakening more than once at night to void * Has usual habit of \< 1 or \> 3 bowel movements per day * Has family history of long QT syndrome or of unexplained sudden death in a first-degree relative under 50 years of age * Has documented congenital or acquired long QT syndrome

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

Contacts and locations

Locations

  • Pharmaron CPC Inc

    Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.